What will happen in the study?
You will be treated with a new drug, ARQ 092 (Miransertib), as we assess its safety and efficacy by looking at overall growth and the pain associated with the lesion(s), your physical functioning, and your overall health.
We expect that you will be in this research study for at least 3 cycles (each cycle is 28 days). However, you may be in the study receiving study medication as long as a total of 48 cycles (about 48 months) if you are benefiting from the therapy in the opinion of the research doctor. 30 days after your last dose of the investigational drug, we will request you come in for one last visit for safety.